Charles River Laboratories International, Inc. (NYSE:CRL) has been assigned a consensus rating of “Buy” from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $95.31.

A number of research analysts have recently commented on CRL shares. Zacks Investment Research lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday. Jefferies Group LLC reaffirmed a “buy” rating and set a $106.00 price objective on shares of Charles River Laboratories International in a research report on Friday, April 21st. Citigroup Inc. reissued a “neutral” rating and issued a $104.00 target price (up previously from $90.00) on shares of Charles River Laboratories International in a research note on Thursday, May 11th. Barclays PLC reissued a “hold” rating and issued a $102.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Finally, BidaskClub raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 20th.

In related news, Director George Massaro sold 1,130 shares of the stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $88.30, for a total value of $99,779.00. Following the transaction, the director now directly owns 15,831 shares in the company, valued at $1,397,877.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman James C. Foster sold 43,154 shares of the stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $100.00, for a total transaction of $4,315,400.00. Following the completion of the transaction, the chairman now owns 361,178 shares in the company, valued at $36,117,800. The disclosure for this sale can be found here. Insiders have sold 80,499 shares of company stock worth $7,946,191 over the last three months. 2.20% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of CRL. Columbus Circle Investors raised its stake in Charles River Laboratories International by 170.2% in the first quarter. Columbus Circle Investors now owns 75,724 shares of the medical research company’s stock valued at $6,811,000 after buying an additional 47,703 shares during the period. BlackRock Inc. raised its stake in Charles River Laboratories International by 12,573.1% in the first quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock valued at $345,915,000 after buying an additional 3,815,298 shares during the period. Gotham Asset Management LLC raised its stake in Charles River Laboratories International by 4,129.0% in the first quarter. Gotham Asset Management LLC now owns 116,298 shares of the medical research company’s stock valued at $10,461,000 after buying an additional 113,548 shares during the period. Mutual of America Capital Management LLC raised its stake in Charles River Laboratories International by 4.3% in the first quarter. Mutual of America Capital Management LLC now owns 38,427 shares of the medical research company’s stock valued at $3,457,000 after buying an additional 1,579 shares during the period. Finally, Quadrature Capital Ltd purchased a new stake in Charles River Laboratories International during the fourth quarter valued at $925,000. Institutional investors own 98.05% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Rating of “Hold” by Brokerages” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/07/28/charles-river-laboratories-international-inc-nysecrl-given-average-rating-of-hold-by-brokerages.html.

Shares of Charles River Laboratories International (CRL) traded down 1.14% during mid-day trading on Friday, hitting $97.32. The stock had a trading volume of 41,384 shares. The stock has a 50-day moving average price of $99.10 and a 200 day moving average price of $90.30. Charles River Laboratories International has a 52 week low of $67.20 and a 52 week high of $102.32. The stock has a market cap of $4.64 billion, a P/E ratio of 28.48 and a beta of 1.03.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, May 10th. The medical research company reported $1.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.15. The firm had revenue of $445.80 million during the quarter, compared to analyst estimates of $437.04 million. Charles River Laboratories International had a net margin of 9.28% and a return on equity of 27.46%. The business’s revenue was up 25.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.98 EPS. On average, equities analysts forecast that Charles River Laboratories International will post $5.10 EPS for the current fiscal year.

Charles River Laboratories International announced that its board has approved a stock buyback plan on Wednesday, May 10th that authorizes the company to buyback $150.00 million in outstanding shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.